

Straumann taps into peri-implantitis treatment by a full acquisition of GalvoSurge Dental AG, a Swiss medical device manufacturer

- The acquisition offers access to a unique solution on the market which completely cleans dental implants with peri-implantitis, setting ideal conditions for successful healing
- The device will be accessible for the European market by the end of June 2023
- The GalvoSurge device is compatible with most dental implant systems

Basel, May 25, 2023: Straumann announces the full acquisition of GalvoSurge, a Swiss medical device manufacturer in the dental field. The acquired company has specialized in implant care and maintenance solutions, offering an innovative concept to support the treatment of peri-implantitis. The device holds the CE mark and it was introduced to the market in 2020.

Guillaume Daniellot, Chief Executive Officer, said: “With the newly acquired GalvoSurge Dental AG, we are well-equipped to meet the increasing demand for peri-implantitis treatments and protect patients from implant loss. This preventive solution significantly improves patient satisfaction and highlights our commitment to advancing our oral care solutions and providing innovative care for patients worldwide.”

The GalvoSurge Dental Implant Cleaning System GS 1000 is compatible with most implant systems. The acquisition enables Straumann to serve patients globally, regardless of the implant system and deliver innovative care for peri-implantitis conditions. The GalvoSurge device is a unique solution which completely removes the biofilm matrix and decontaminates the affected implant surface, without harming healthy soft and hard tissue.

Peri-implantitis is a complication that must be taken seriously. It is characterized by inflammation and bone loss that can likely result in implant loss if left untreated. Therefore, clinicians are increasingly looking for solutions to treat such post-implant complications, aiming for long-lasting healthy dental implants. Eliminating biofilm is essential for the successful treatment of patients with peri-implantitis, or peri-implant mucositis. The GalvoSurge device uses an electrolytic cleaning principle for biofilm removal. This is accomplished within two minutes and without the need for conventional grinding and brushing.

By June 30, 2023, Straumann will begin offering the device on its eShop in Europe which ensures the supply for existing customers and enables continuation of patient treatments. The official launch is planned for the second half of 2023 under the flagship and premium brand Straumann.

About GalvoSurge

GalvoSurge Dental AG is a Swiss manufacturer of dental devices and equipment, founded in 2015 with headquarters in Widnau (SG). The company has developed a dental implant cleaning system to remove microorganisms (biofilm) from exposed, electrically conductive dental implants anchored in the jawbone – quickly, gently, and effectively.

About Straumann Group

The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Dental Wings, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CAD/CAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss.

Headquartered in Basel, Switzerland, the Group currently employs more than 10'400 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland

Phone: +41 (0)61 965 11 11

Homepage: www.straumann-group.com

Contacts:**Corporate Communication**

E-mail: corporate.communication@straumann.com

Investor Relations

Marcel Kellerhals: +41 (0)61 965 17 51

E-mail: investor.relations@straumann.com

Disclaimer

This release contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this document. Statements are made on the basis of management's views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann's control. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. This release constitutes neither an offer to sell nor a solicitation to buy any securities.

###